Jenny Reardon: The Science and Ethics of Genomics

Dr. Jenny Reardon, author of The Post-Genomic Condition, shifted from experimental molecular biology to Science and Technology Studies (STS) to address societal and ethical questions that could not be answered within the laboratory.

The Human Genome Project (HGP), launched in the late 1980s/early 1990s, was primarily a technical information challenge to translate biological DNA sequences into computer-readable data rather than a biological engineering feat.

The public HGP effort sequenced the genome of an anonymous collective, utilizing 10 donors recruited via a 1-800 number in Albany, New York.

The initial cost of the HGP was approximately $3 billion, equating to roughly $1 per nucleotide.

Dr. Reardon notes that the industry has achieved the "1,000-dollar genome" goal, reducing sequencing costs by a factor of roughly one million since the project's completion.

The public and private sequencing efforts utilized different human individuals, raising early questions regarding the specific identity and representation of "the human genome."

Current genomic analysis has generated petabytes of data, moving from millions of nucleotides in the late 1990s to billions and beyond.

The primary challenge in the post-genome era is interpreting the biological significance of variants, particularly "variants of unknown significance" (VUS).

A specific medical hurdle involves the BRCA1 and BRCA2 genes, which are massive in genomic footprint and contain tens of thousands of variants, many of which lack defined clinical meaning.

Dr. Reardon argues against the expectation that genomics will "cure" cancer, characterizing cancer as a natural result of mutation and evolution rather than a disease to be eradicated.

Immunotherapies that redesign T-cells based on genomic data show high efficacy but carry risks of off-target attacks on healthy organs, such as the liver, which can be fatal.

The "common disease, common variant" hypothesis has largely failed; common diseases are now understood to be driven largely by rare variants rather than common ones.

The economic value of an individual's genome is negligible without the context of a massive comparative dataset involving millions of other genomes.

The industry model shifted from individual-centric ("23andMe") to population-centric ("23andWe") because meaning is derived exclusively through comparative genomics.

23andMe and similar companies create value by aggregating user data to sell insights to pharmaceutical firms for drug discovery and patient recruitment.

Genetic Non-Discrimination Act (GINA) of 2008 prohibits health insurance discrimination based on genetic information but contains significant loopholes.

GINA does not cover life insurance, disability insurance, or long-term care insurance, creating vulnerabilities for conditions like Alzheimer's disease.

Pharmaceutical companies are increasingly utilizing consumer genomic databases to identify asymptomatic patients with rare diseases to facilitate clinical trials.

Genomic data from personal testing and open-source projects is increasingly used by law enforcement for criminal investigations, as demonstrated by the resolution of the Golden State Killer case via familial DNA matching.

Researchers and companies debate the ethics of using volunteer DNA databases for national security or law enforcement purposes against the original intent of the contributors.

Reardon highlights the risk that information sold by testing companies to third parties (e.g., pharma) may be used in ways that violate the original donor's ethical expectations.

Gene editing tools (e.g., CRISPR) are not precision instruments like word processors; success rates vary, with failure rates potentially ranging from 20% to 50% depending on the application.

Failed editing attempts can result in off-target mutations or malformed organisms, drawing historical parallels to the high mortality rates seen in early cloning attempts (e.g., Dolly the sheep).

Dr. Reardon emphasizes that biological complexity makes "messy" outcomes a reality, challenging the narrative of "precision medicine."

Ethical concerns persist regarding the historical precedent of experimenting on vulnerable populations, referencing past surgical advancements derived from experiments on enslaved people.

The 1999 death of Jesse Gelsinger during early gene therapy trials remains a central cautionary tale regarding the risks of human experimentation in biomedical advancement.